CoChat

Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectories in individuals who developed type 2 diabetes. RESEARCH DESIGN AND METHODS: This case-cohort study, nested within the Whitehall II cohort, was based on 335 incident type 2 diabetes cases and 2,475 noncases. We measured serum IL-1Ra levels at up to three time points per individual and estimated retrospective trajectories of IL-1Ra before diabetes diagnosis (case subjects) or end of follow-up (control subjects) using multilevel analysis. Models were adjusted for age, sex, and ethnicity. RESULTS: IL-1Ra levels were already higher in the case than control subjects 13 years before diabetes diagnosis/end of follow-up (mean [95% CI] 302 [290–314] vs. 244 [238–249] pg/ml). In control subjects, IL-1Ra levels showed a modest linear increase throughout the study period. In case subjects, IL-1Ra trajectories were parallel to those in control subjects until 6 years (95% CI 7.5–4.5) before diagnosis and then rose steeply to 399 (379–420) pg/ml at the time of diagnosis (P < 0.0001 for slope difference). Adjustment for BMI and waist circumference as time-varying covariates had little impact on these trajectories. CONCLUSIONS: We show elevated IL-1Ra levels for 13 years and an accelerated increase during the last 6 years before type 2 diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-1199

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. A–D: Model-predicted IL-1Ra trajectories in nondiabetic and incident diabetic subjects. Year 0 denotes the time of diagnosis for case subjects and a randomly selected time point during follow-up for control subjects (noncases). All models were adjusted for age, sex, and ethnicity. Additional adjustment was performed for BMI (B), waist circumference (C), and fasting insulin (D). The table below the panels shows the number of measurements at each time point for both case and control subjects. Error bars represent 95% CIs around the values estimated by the fixed effect part of the mixed model presented in Table 4.
FIG. 1. A–D: Model-predicted IL-1Ra trajectories in nondiabetic and incident diabetic subjects. Year 0 denotes the time of diagnosis for case subjects and a randomly selected time point during follow-up for control subjects (noncases). All models were adjusted for age, sex, and ethnicity. Additional adjustment was performed for BMI (B), waist circumference (C), and fasting insulin (D). The table below the panels shows the number of measurements at each time point for both case and control subjects. Error bars represent 95% CIs around the values estimated by the fixed effect part of the mixed model presented in Table 4.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 137

Metadata

Authors
Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G.
Affiliations
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Department of Epidemiology and Public Health, University College London, London, U.K.;
  • University College London (GB)
  • Düsseldorf University Hospital (DE)
Corresponding author
Herder, Christian
Venue
Diabetes
Published
2010-02-25
Volume
59
Issue
5
Pages
1222-1227
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2126985857
Cited by
137
References
38
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 10
FWCI
9.77
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • John D. and Catherine T. MacArthur Foundation
  • British Heart Foundation (RG/07/008/23674)
  • Bupa Foundation
  • Health and Safety Executive
  • Academy of Finland
  • Bundesministerium für Gesundheit
  • Novo Nordisk
  • National Institutes of Health
  • Agency for Healthcare Research and Quality (HS06516)
  • Medical Research Council
  • Economic and Social Research Council
  • National Institute on Aging (AG 13196, R37AG013196, R01AG013196)
  • National Heart, Lung, and Blood Institute (R01HL036310)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
interleukin-1 receptor antagonist, type 2 diabetes, prediabetes, serum biomarkers, biomarker trajectories, anti-inflammatory response, inflammation, beta-cell function, Whitehall II cohort
MeSH terms
Adult, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Cohort Studies, Interleukin 1 Receptor Antagonist Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db09-1199
The paper
Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G. (2010). Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db09-1199

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.